The ultimate goal is to be able to design precision treatment plans for each patient, principal scientist Michael Pazzani, PhD, said in a Nov. 22 university news release.
“There are a number of drugs for Parkinson’s disease that unfortunately are only about 25 percent effective, but for a certain group of patients they’re 90 percent effective,” he stated. “So if you can understand the relationship between a patient’s genetic background and the drug, then you can tailor a drug to a specific patient or a specific group of patients.”
AI4Health will be located at the USC Information Sciences Institute in Marina del Rey, Calif.
